^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
gemcitabine oral (D07001)
i
Other names: D07001, D07001-F4, Inno-D07001
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Synmosa Biopharma
Drug class:
DNA synthesis inhibitor
Related drugs:
7ms
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
P3, N=195, Not yet recruiting, InnoPharmax Inc. | Initiation date: Apr 2025 --> Jul 2025
Trial initiation date
|
5-fluorouracil • capecitabine • irinotecan • leucovorin calcium • gemcitabine oral (D07001)
1year
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
P3, N=195, Not yet recruiting, InnoPharmax Inc.
New P3 trial
|
5-fluorouracil • capecitabine • irinotecan • leucovorin calcium • gemcitabine oral (D07001)
2years
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase (clinicaltrials.gov)
P1/2, N=19, Completed, InnoPharmax Inc. | Terminated --> Completed
Trial completion
|
gemcitabine oral (D07001)
almost5years
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase (clinicaltrials.gov)
Recruiting --> Active, not recruiting | Trial completion date: May 2020 --> Apr 2022 | Trial primary completion date: Oct 2019 --> Jun 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
ALB (Albumin)
|
gemcitabine oral (D07001)
Share via
